India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
India is planning to construct a massive ₹40,000 crore subsea gas pipeline from Oman to…
Modern air combat is entering a revolutionary phase. While several countries are still developing 6th-generation…
Ethanol emerged as largest ethanol feedstock for the first time in ethanol program of the…
Uber is partnering with the Adani Group to build its first data centre in the…
The BRICS Foreign Ministers Meeting begins on 14th May, 2026 in the New Delhi. It…
Indian FinTech company FinBox has launched the Atlas which is an AI-native lending infrastructure platform…